The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors.
We aimed to identify whether abdominal fat distribution could affect the outcome in metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs) or not. A total of 42 MBC patients treated with first line hormonal therapy were enrolled in this study. Factors associated with overall survival in the univariate analysis were age, c-erb-B2 expression intensity (+++ versus others by immunohistochemistry), and WHR, whereas only WHR retained significance in the multivariate analysis. Median overall survival figures were 472 days versus unreached for patients with a WHR of <0.92 and >or=0.92 (Log rank statistic=9.76, P=0.002). Similarly, the corresponding progression free survival figures for patients with a WHR of <0.92 and >or=0.92 were 423 versus 1004 days (Log rank statistic=6.37, P=0.012). This study suggests that WHR may serve as a potential predictive marker in MBC patients treated with AIs.
Artac
Mehmet
M
Division of Medical Oncology, Meram Medical Faculty, Selcuk University, Konya, Turkey. martac@selcuk.edu.tr
Bozcuk
Hakan
H
Afacan
Berna
B
Ozdogan
Mustafa
M
Samur
Mustafa
M
D050153:Abdominal Fat; D000328:Adult; D000368:Aged; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D050218:Body Fat Distribution; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D011237:Predictive Value of Tests; D015996:Survival Rate; D049629:Waist-Hip Ratio
D047072:Aromatase Inhibitors